Literature DB >> 9489481

How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone?

H Taubert1, D Berger, R Hinze, A Meye, P Würl, P C Hogendoorn, H J Holzhausen, H Schmidt, F W Rath.   

Abstract

Both tumor suppressor genes p53 and p16(INK4A) play a crucial role in the control of cell cycle and tumor development. In this study 19 malignant fibrous histiocytomas of the bone (MFH-b), a very rare sarcoma entity, were investigated for mutations in p53 and p16 genes by a PCR-SSCP-sequencing analysis. In the tumor samples two p53 mutations and two polymorphisms (one in the p53 gene and one in the p16 gene) were found. The occurrence rate for p53 mutations and the absence of p16 mutations in MFH-b are comparable to the findings for MFH of soft tissues (MFH-st) and osteosarcomas, suggesting that p53 rather than p16 may play a role in tumorigenesis of MFH-b.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489481     DOI: 10.1016/s0304-3835(97)00423-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

Review 1.  Diagnostic and prognostic implications of the unfolding molecular biology of bone and soft tissue tumours.

Authors:  J F Graadt van Roggen; J V Bovée; J Morreau; P C Hogendoorn
Journal:  J Clin Pathol       Date:  1999-07       Impact factor: 3.411

2.  Reclassification and subtyping of so-called malignant fibrous histiocytoma of bone: comparison with cytogenetic features.

Authors:  Fredrik Mertens; Salvatore Romeo; Judith Vmg Bovée; Roberto Tirabosco; Nick Athanasou; Marco Alberghini; Pancras Cw Hogendoorn; Angelo P Dei Tos; Raf Sciot; Henryk A Domanski; Kristina Aström; Nils Mandahl; Maria Debiec-Rychter
Journal:  Clin Sarcoma Res       Date:  2011-10-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.